Drug Trial Radar · NCT05599984
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
288
Actual
Start
Dec 5, 2022
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Oct 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy and in combination with budigalimab, carboplatin, or cisplatin. ABBV-706 is an investigational drug being developed for the treatment of small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine carcinomas (NECs). There are multiple treatment arms in this study. Participants will either receive ABBV-706 as a single agent or in combination with budigalimab (another investigational drug), carboplatin or cisplatin at different doses. Approximately 319 adult participants will be enrolled in the study across sites worldwide. In part 1 (dose escalation), ABBV-706 will be intravenously infused in escalating doses as a monotherapy until the maximum tolerated dose (MTD) is determined in participants with SCLC, high-grade CNS tumors, and high-grade NECs. In part 2, multiple doses will be selected from Part 1 and SCLC participants will be assigned to one of these doses in a randomized fashion to determine the recommended Phase 2 dose. In Part 3a, participants with SCLC or NECs will receive ABBV-706 in combination with budigalimab intravenously every 3 weeks. In Part 3b participants with SCLC or NECs will receive ABBV-706 in combination with either carboplatin or cisplatin intravenously. In Part 4a, participants with CNS tumors will receive ABBV-706 intravenously at a dose determined from Part 1. In Part 4b, participants with NECs will receive ABBV-706 intravenously at a dose selected from Part 1. The estimated duration of the study is up to 4 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Conditions
- Advanced Solid Tumors
Interventions
ABBV-706Drug
Intravenous (IV) Infusion
CisplatinDrug
Intravenous infusion
BudigalimabDrug
IV Infusion
CarboplatinDrug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adverse Events (AE)Time frame: Up to Approximately 2 Years
- Maximum Observed Serum/Plasma Concentration (Cmax) of ABBV-706Time frame: Up to Approximately 2 Years
- Time to Cmax (Tmax) of ABBV-706Time frame: Up to Approximately 2 Years
- Terminal Phase Elimination Half-Life (t1/2) of ABBV-706Time frame: Up to Approximately 2 Years
- Area Under the Serum/Plasma Concentration-Time Curve (AUC) of ABBV-706Time frame: Up to Approximately 2 Years
- Antidrug Antibodies (ADAs)Time frame: Up to Approximately 2 Years
- Neutralizing Antibodies (nAbs)Time frame: Up to Approximately 2 Years
- Percentage of Participants with Objective Response, for Participants with Extracranial Solid TumorsTime frame: Up to Approximately 2 Years
- Recommended Phase 2 Dose (RP2D) of ABBV-706Time frame: Up to Approximately 2 Years
- Percentage of Participants with Objective Response for Participants with Central Nervous System (CNS) TumorsTime frame: Up to Approximately 2 Years
- Duration of response (DOR) for Participants with Confirmed CR/PRTime frame: Up to Approximately 2 Years
- Percentage of Participants with Clinical BenefitTime frame: Up to Approximately 2 Years
- Progression-Free Survival (PFS)Time frame: Up to Approximately 2 Years
- Overall survival (OS)Time frame: Up to Approximately 2 Years
Locations
66 sites in 10 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Ctr /ID# 260129
Gilbert, Arizona
City Of Hope Comprehensive Cancer Center /ID# 271295
Duarte, California
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 259884
Irvine, California
Yale New Haven Hospital /ID# 246647
New Haven, Connecticut
Georgetown University Hospital /ID# 255352
Washington D.C., District of Columbia
University of Chicago Medical Center /ID# 256334
Chicago, Illinois
Fort Wayne Medical Oncology and Hematology, Inc /ID# 260130
Fort Wayne, Indiana
University of Iowa Hospitals and Clinics /ID# 246638
Iowa City, Iowa
Barbara Ann Karmanos Cancer In /ID# 261799
Detroit, Michigan
Henry Ford Hospital /ID# 246648
Detroit, Michigan
START Midwest /ID# 251257
Grand Rapids, Michigan
St. Lukes Hosp. of Kansas City /ID# 259958
Kansas City, Missouri
Washington University-School of Medicine /ID# 246286
St Louis, Missouri
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 246303
New York, New York
Duke Cancer Center /ID# 246285
Durham, North Carolina
UH Cleveland Medical Center /ID# 246641
Cleveland, Ohio
Univ Oklahoma HSC /ID# 250884
Oklahoma City, Oklahoma
Tennessee Oncology, PLLC /ID# 246283
Nashville, Tennessee
University of Texas MD Anderson Cancer Center /ID# 246287
Houston, Texas
South Texas Accelerated Research Therapeutics /ID# 248946
San Antonio, Texas
University of Utah /ID# 246640
Salt Lake City, Utah
Northwest Medical Specialties - Tacoma /ID# 262801
Tacoma, Washington
Chris O'Brien Lifehouse /ID# 259087
Camperdown, New South Wales, Australia
The Kinghorn Cancer Centre /ID# 260874
Darlinghurst, New South Wales, Australia
Austin Health and Ludwig Institute for Cancer Research /ID# 255174
Heidelberg, Victoria, Australia
Peter MacCallum Cancer Ctr /ID# 259197
Melbourne, Victoria, Australia
Cancer Hospital - Chinese Academy Of Medical Sciences /ID# 270044
Beijing, Beijing Municipality, China
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 270038
Wuhan, Hubei, China
First Affiliated Hospital of China Medical University /ID# 270041
Shenyang, Liaoning, China
Shanghai Chest Hospital /ID# 270036
Shanghai, Shanghai Municipality, China
Shanghai East Hospital /ID# 268615
Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital /Id# 270039
Shanghai, Shanghai Municipality, China
Institut Régional du Cancer Montpellier /ID# 265086
Montpellier, France
Institut Bergonie /ID# 258655
Bordeaux, Gironde, France
Institut Gustave Roussy /ID# 260334
Villejuif, Val-de-Marne, France
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin /ID# 259413
Berlin, Germany
Klinikum der Universitaet Muenchen - Campus Innenstadt /ID# 259412
Munich, Bavaria, Germany
Universitaetsklinikum Carl Gustav Carus Dresden /ID# 259414
Dresden, Saxony, Germany
Rambam Health Care Campus /ID# 255059
Haifa, Israel
Hadassah Medical Center-Hebrew University /ID# 255147
Jerusalem, Israel
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.